Holen Sie sich die Stockscreener-App
18.12
0.17%
-0.0236
Schlusskurs vom Vortag:
$18.14
Offen:
$17.97
24-Stunden-Volumen:
121.29K
Relative Volume:
0.06
Marktkapitalisierung:
$1.30B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-213.70M
KGV:
-5.444
EPS:
-3.3278
Netto-Cashflow:
$-185.90M
1W Leistung:
+2.43%
1M Leistung:
+22.61%
6M Leistung:
-69.53%
1J Leistung:
-54.71%
1-Tages-Spanne:
$17.87
$18.33
1-Wochen-Bereich:
$17.00
$18.33
52-Wochen-Spanne:
$5.95
$62.75
Moonlake Immunotherapeutics Stock (MLTX) Company Profile
Firmenname
Moonlake Immunotherapeutics
Sektor
Branche
Telefon
41 41 510 8022
Adresse
DORFSTRASSE 29, ZUG
Compare MLTX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MLTX
Moonlake Immunotherapeutics
|
18.11 | 1.30B | 0 | -213.70M | -185.90M | -3.3278 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.37 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
768.63 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
726.83 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
323.11 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
294.78 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-15 | Herabstufung | Goldman | Neutral → Sell |
| 2026-01-09 | Hochstufung | BTIG Research | Neutral → Buy |
| 2025-11-03 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-10-02 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-10-01 | Herabstufung | Goldman | Buy → Neutral |
| 2025-09-30 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-09-30 | Herabstufung | Wolfe Research | Outperform → Underperform |
| 2025-09-29 | Herabstufung | BTIG Research | Buy → Neutral |
| 2025-09-29 | Herabstufung | Jefferies | Buy → Hold |
| 2025-09-29 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-09-29 | Herabstufung | Stifel | Buy → Hold |
| 2025-07-28 | Eingeleitet | Rothschild & Co Redburn | Neutral |
| 2025-05-19 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-03-18 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-01-17 | Hochstufung | Goldman | Neutral → Buy |
| 2024-11-05 | Fortgesetzt | Wedbush | Outperform |
| 2024-08-26 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | Eingeleitet | Oppenheimer | Outperform |
| 2024-04-02 | Eingeleitet | Goldman | Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-08 | Eingeleitet | Citigroup | Buy |
| 2023-11-02 | Eingeleitet | Stifel | Buy |
| 2023-09-14 | Herabstufung | Bryan Garnier | Buy → Neutral |
| 2023-08-31 | Eingeleitet | Needham | Buy |
| 2023-06-15 | Eingeleitet | Barclays | Equal Weight |
| 2023-05-01 | Eingeleitet | Guggenheim | Buy |
| 2023-03-22 | Eingeleitet | Wedbush | Outperform |
| 2023-03-09 | Eingeleitet | BTIG Research | Buy |
| 2023-02-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-02-02 | Eingeleitet | Bryan Garnier | Buy |
| 2022-11-11 | Eingeleitet | Jefferies | Buy |
| 2022-08-25 | Eingeleitet | SVB Leerink | Outperform |
| 2022-07-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-07-07 | Eingeleitet | Cowen | Outperform |
Alle ansehen
Moonlake Immunotherapeutics Aktie (MLTX) Neueste Nachrichten
HC Wainwright Issues Negative Outlook for MLTX Earnings - MarketBeat
What is HC Wainwright's Estimate for MLTX FY2027 Earnings? - MarketBeat
Wedbush Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $34 - 富途牛牛
MoonLake Immunotherapeutics (MLTX) Stock Analysis: Exploring a 34.94% Upside in the Biotech Sphere - DirectorsTalk Interviews
Cantor Fitzgerald reiterates Moonlake stock rating on axSpA potential - Investing.com
MoonLake Immunotherapeutics price target raised to $40 from $32 at H.C. Wainwright - TipRanks
MoonLake Immunotherapeutics (MLTX) Is Down 6.3% After Wider 2025 Loss And SLK BLA Timeline Update – Has The Bull Case Changed? - simplywall.st
MLTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Royal Bank Of Canada Boosts MoonLake Immunotherapeutics (NASDAQ:MLTX) Price Target to $13.00 - MarketBeat
Goldman Questions MoonLake Immunotherapeutics' (MLTX) Sonelokimab Approval Odds Despite Pipeline Update - Finviz
MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
RBC Raises Price Target on MoonLake Immunotherapeutics to $13 From $12, Keeps Sector Perform, Speculative Risk - marketscreener.com
Moonlake Immunotherapeutics stock price target raised to $40 by H.C. Wainwright on trial results - Investing.com
MoonLake Immunotherapeutics price target raised to $35 from $30 at Oppenheimer - TipRanks
Stifel Downgrades MoonLake Immunotherapeutics(MLTX.US) to Hold Rating, Cuts Target Price to $19 - 富途牛牛
Assessing MoonLake Immunotherapeutics (MLTX) Valuation After Mixed Share Price Performance And Premium P/B Ratio - Yahoo Finance
MoonLake’s Sonelokimab Data Sharpens Risk Reward Profile Before Phase 3 - simplywall.st
MoonLake Immunotherapeutics (MLTX) Is Down 6.7% After Mixed 2025 Results And AxSpA Data UpdateWhat's Changed - Yahoo Finance
MoonLake shares climb on encouraging AXSPA trial results - MSN
Goldman Sachs Maintains MoonLake Immunotherapeutics(MLTX.US) With Sell Rating, Raises Target Price to $11 - 富途牛牛
MoonLake Immunotherapeutics price target raised to $11 from $10 at Goldman Sachs - TipRanks
MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Rating Upgraded by Zacks Research - MarketBeat
Decoding MoonLake Immunotherapeutics (MLTX): A Strategic SWOT Insight - GuruFocus
(MLTX) Volatility Zones as Tactical Triggers - Stock Traders Daily
MoonLake Immunotherapeutics (NASDAQ:MLTX) Posts Earnings Results - MarketBeat
Quarterly Earnings: Is MoonLake Immunotherapeutics stock a falling knife or bargain buyJuly 2025 Volume & Consistent Return Strategy Ideas - baoquankhu1.vn
Lifesci Capital Has Optimistic Outlook of MLTX Q4 Earnings - MarketBeat
MoonLake Immunotherapeutics SEC 10-K Report - TradingView
MoonLake Immunotherapeutics (MLTX) Stock Analysis: Unveiling a 12.8% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Assessing MoonLake Immunotherapeutics (MLTX) Valuation After Positive Phase 2 S-OLARIS Trial Results - simplywall.st
MoonLake: Downgrade To Buy As Sonelokimab Still Has A BLA Shot On Goal (NASDAQ:MLTX) - Seeking Alpha
MoonLake turns the tables on sonelokimab with positive data - The Pharma Letter
Citi Maintains MoonLake Immunotherapeutics(MLTX.US) With Sell Rating, Raises Target Price to $6 - 富途牛牛
A Quick Look at Today's Ratings for MoonLake Immunotherapeutics(MLTX.US), With a Forecast Between $20 to $34 - 富途牛牛
MoonLake Immunotherapeutics (MLTX) Price Target Increased by 11.25% to 22.30 - Nasdaq
Oppenheimer Adjusts Price Target on MoonLake Immunotherapeutics to $35 From $30, Maintains Outperform Rating - marketscreener.com
Guggenheim Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Cuts Target Price to $20 - 富途牛牛
Needham & Company LLC Issues Positive Forecast for MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price - MarketBeat
MoonLake Immunotherapeutics (NASDAQ:MLTX) Price Target Raised to $30.00 - MarketBeat
MoonLake Immunotherapeutics Investor Day: HS BLA on Track, axSpA Phase 2 Data Highlights Imaging Wins - MarketBeat
MoonLake Expects To File Sonelokimab For HS Later In 2026 - Citeline News & Insights
MoonLake touts Phase II sonelokimab results in spine disease study - FirstWord Pharma
Needham Raises MoonLake Immunotherapeutics' Price Target to $25 From $20, Buy Rating Kept - marketscreener.com
MoonLake stock surges 63% after InvestingPro Fair Value call By Investing.com - Investing.com UK
MLTX: BLA submission for SLK in HS on track, supported by robust efficacy, safety, and financial runway - TradingView
MoonLake Immunotherapeutics (MLTX) Is Up 19.0% After Positive Phase 2 Axial Spondyloarthritis Data ReleaseHas The Bull Case Changed? - simplywall.st
MLTX: BLA submission for SLK in HS on track, supported by robust efficacy and safety data - TradingView
MoonLake's sonelokimab shows strong Phase II efficacy in axSpA, challenging UCB’s Bimzelx - European Biotechnology Magazine
Why Is MoonLake Immunotherapeutics Stock Trading Higher TodayMoonLake (NASDAQ:MLTX) - Benzinga
MoonLake stock surges on positive axSpA trial data By Investing.com - Investing.com South Africa
MoonLake stock surges on positive axSpA trial data - Investing.com India
Finanzdaten der Moonlake Immunotherapeutics-Aktie (MLTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Moonlake Immunotherapeutics-Aktie (MLTX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Santos da Silva Jorge | Chief Executive Officer |
Dec 09 '25 |
Sale |
14.49 |
70,000 |
1,014,300 |
2,878,577 |
| Reich Kristian | Chief Scientific Officer |
Dec 08 '25 |
Sale |
15.08 |
130,000 |
1,960,400 |
72,908 |
| Reich Kristian | Chief Scientific Officer |
Dec 09 '25 |
Sale |
14.43 |
72,908 |
1,052,062 |
0 |
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):